Skoopin Inc – Trademark Portfolio
Entity Type: 03
Skoopin Inc holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 2 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 5 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include SKOOPIN and METAFOODX. The owner is based in San Jose, CA.
160 E Tasman Drive
San Jose, CA 95134
Showing of trademarks Trademarks
Trademark Classifications
Skoopin Inc's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Skoopin Inc have?
Skoopin Inc has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does Skoopin Inc file in?
Skoopin Inc files trademarks across 5 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 42 (Computer & Scientific), Class 9 (Computers & Electronics), Class 44 (Medical Services), Class 43 (Hotels & Restaurants). Class 35 covers advertising; business management; business administration; office functions.
What are Skoopin Inc's most well-known trademarks?
Skoopin Inc's registered trademark portfolio includes well-known marks such as SKOOPIN and METAFOODX. These are among 2 currently registered trademarks in the portfolio.
What is Skoopin Inc's trademark registration success rate?
Skoopin Inc has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.